- This topic has 1 reply, 2 voices, and was last updated 1 year, 5 months ago by .
Viewing 0 reply threads
-
Posts
-
-
“The EMPEROR-Preserved trial is the first randomized controlled trial testing the efficacy and safety of SGLT2 inhibitors (empagliflozin) in patients with HFpEF. The EMPEROR-Preserved trial has proven that SGLT2 inhibitors can significantly reduce HF hospitalization with neutral effect on cardiovascular (CV) death, and now the door is open for further exploration by other members of the SGLT2 family in also reducing CV mortality in HFpEF patients”.
Wagdy K, Nagy S. EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction. Glob Cardiol Sci Pract. 2021 Oct 30;2021(3):e202117. doi: 10.21542/gcsp.2021.17. PMID: 34805375; PMCID: PMC8587377.
-
Viewing 0 reply threads
- You must be logged in to reply to this topic.